Summary
Gilead Sciences, Inc. (GILD) reported its first quarter 2002 financial results, showing significant revenue growth driven by the initial sales of Viread, an HIV treatment, which is beginning to diversify the company's revenue base beyond its established antifungal drug, AmBisome. Despite the revenue increase, the company continued to experience a net loss, though it narrowed compared to the prior year's quarter. This is primarily due to increased Selling, General, and Administrative (SG&A) expenses related to the launch of Viread and ongoing Research and Development (R&D) investments. Gilead's balance sheet shows a healthy cash and marketable securities position, providing adequate resources for ongoing operations and development. The company has also recently made strategic moves, including filing for regulatory approval for adefovir dipivoxil for Hepatitis B and entering into a licensing agreement with GlaxoSmithKline for this compound in certain territories. Investors should note the significant increase in SG&A expenses, which are expected to continue as Gilead expands its commercialization efforts. While Viread shows strong initial promise, AmBisome sales saw a slight decline, partly due to foreign currency fluctuations. The company remains focused on its pipeline, particularly for infectious diseases, and manages its market risk through hedging strategies for foreign currency exposure.
Key Highlights
- 1Total revenues increased by 28.6% to $78.4 million for Q1 2002 from $57.8 million in Q1 2001.
- 2Net product sales grew significantly by 56.9% to $70.7 million in Q1 2002 from $45.1 million in Q1 2001, driven by the launch of Viread.
- 3Viread contributed $27.2 million in net product sales in its first full quarter on the market, becoming a substantial revenue driver alongside AmBisome.
- 4AmBisome sales experienced a 5% decline year-over-year, indicating diversification efforts are underway and highlighting foreign currency impacts.
- 5Research and Development (R&D) expenses decreased by 34% to $33.6 million, largely due to a one-time payment in the prior year, while Selling, General, and Administrative (SG&A) expenses more than doubled to $39.8 million to support Viread's launch.
- 6The company's net loss narrowed to $3.85 million ($0.02 per share) in Q1 2002, an improvement from a net loss of $21.7 million ($0.11 per share) in Q1 2001.
- 7Gilead filed for regulatory approval for adefovir dipivoxil (HBV treatment) and entered into a significant licensing agreement with GlaxoSmithKline for this compound.